Guidance for Industry on Organ-Specific Warnings:

Federal Register: August 17, 2010 (Volume 75, Number 158)

Notices

Page 50770

From the Federal Register Online via GPO Access [wais.access.gpo.gov]

DOCID:fr17au10-59

Page 50770

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Docket No. FDA-2010-D-0404

Guidance for Industry on Organ-Specific Warnings: Internal

Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-

Counter Human Use--Small Entity Compliance Guide; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of a guidance for small business entities entitled ``Organ

Specific Warnings: Internal Analgesic, Antipyretic, and Antirheumatic

Drug Products for Over-the-Counter Use--Small Entity Compliance

Guide.'' This guidance is intended to help small businesses understand and comply with FDA's regulation entitled ``Organ-Specific Warnings:

Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for

Over-the-Counter Use; Final Monograph'' (74 FR 19385, April 29, 2009).\1\ The guidance describes the organ-specific labeling requirements in plain language and provides answers to common questions on how to comply with the rule. This guidance was prepared in accordance with the Small Business Regulatory Fairness Act.

\1\ As amended November 25, 2009 (74 FR 61512).

DATES: Submit either electronic or written comments on agency

guidances at any time.

ADDRESSES: Submit written requests for single copies of this guidance to the Division of Drug Information, Center for Drug Evaluation and

Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, rm. 2201, Silver Spring, MD 20993-0002. Send one self-addressed adhesive label to assist that office in processing your requests. See the SUPPLEMENTARY INFORMATION section for electronic access to the guidance document.

Submit electronic comments on the guidance to http:// www.regulations.gov. Submit written comments to the Division of Dockets

Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Arlene Solbeck, Center for Drug

Evaluation and Research, Food and Drug Administration, 10903 New

Hampshire Ave., Bldg. 22, rm. 5426, Silver Spring, MD 20993-0002, 301- 796-2090.

SUPPLEMENTARY INFORMATION:

1. Background

   FDA is announcing the availability of a new guidance for small business entities entitled ``Organ-Specific Warnings: Internal

   Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-

   Counter Human Use--Small Entity Compliance Guide.'' This small entity compliance guide applies to over-the-counter (OTC) internal analgesic, antipyretic, and antirheumatic (IAAA) drug products that contain acetaminophen or nonsteroidal anti-inflammatory drug ingredients

   (NSAIDs). The labeling of those products must include specific warnings about the risks of liver injury when using acetaminophen, and stomach bleeding when using nonsteroidal NSAIDs, as well as related information appearing on the principal display panel. Manufacturers must be in compliance with the rule beginning on April 29, 2010.

   This guidance is being issued consistent with FDA's good guidance practices regulation (21 CFR 10.115). The guidance represents the agency's current thinking on organ-specific labeling requirements for

   OTC IAAA drug products. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the requirements of the applicable statutes and regulations.

2. Comments

   Interested persons may submit to the Division of Dockets Management

   (see ADDRESSES) either electronic or written comments regarding this document. It is only necessary to send one set of comments. It is no longer necessary to send two copies of mailed comments. Identify comments with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets

   Management between 9 a.m. and 4 p.m., Monday through Friday.

3. Electronic Access

   Persons with access to the Internet may obtain the document at either http://www.fda.gov/Drugs/

   GuidanceComplianceRegulatoryInformation/Guidances/default.htm or http:/

   /www.regulations.gov.

   Dated: August 5, 2010.

   Leslie Kux,

   Acting Assistant Commissioner for Policy.

   FR Doc. 2010-20252 Filed 8-16-10; 8:45 am

   BILLING CODE 4160-01-S